PerkinElmer Completes Acquisition of Pediatrix's Newborn Metabolic Screening Business

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 29, 2008--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences, today announced that it has successfully completed its acquisition of the newborn metabolic screening business of Pediatrix Medical Group, Inc. (NYSE: PDX). The completion of this transaction expands PerkinElmer's capabilities in the neonatal health field.

PerkinElmer has added Pediatrix's screening reference laboratory and its StepOne(R) newborn screening product, which is capable of analyzing more than 50 inherited disorders in newborns, to its genetic screening product offerings. The laboratory provides neonatal screening and consultative services to five states and the District of Columbia, as well as to hospitals and medical groups.

"Our strategy is for PerkinElmer to enhance its capability to deliver a growing portfolio of world-class neonatal and prenatal/maternal health solutions to consumers through their healthcare professionals," said Robert F. Friel, Chief Executive Officer and President of PerkinElmer. "With the completion of this acquisition, we now can provide state laboratories with the most comprehensive array of newborn screening solutions available and strengthen our leadership in this growing market."